At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 60 target
Drug / intervention
ZGGS18 for Injection +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors, Including Cervical Cancer, Hepatocellular Carcinoma, Neuroendocrine Tumors, and Lung Cancer
In Brief
A Phase 2 clinical trial evaluating ZGGS18 for Injection and ZG005 for Injection for Advanced Solid Tumor. Currently recruiting, targeting 60 participants across 1 site.
Detailed Summary
This trial is designed to assess the tolerability, safety, pharmacokinetic profile, and preliminary efficacy of the combination of ZGGS18 and ZG005 in patients with advanced solid tumors, including advanced cervical cancer, hepatocellular carcinoma, neuroendocrine cancer, and lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
202620272028
First PostedApr 2025
Enrollment StartMay 2025
TodayJul 2026
Primary CompletionMay 2027
Study CompletionApr 2028
First PostedApr 22, 2025
Enrollment StartMay 20, 2025
Primary CompletionMay 1, 2027
Study CompletionApr 1, 2028
TodayJul 1, 2026
Enrollment to primary: 1.9 yearsPosted 1.2 years agoPrimary completion in 10 months
Interventions
ZGGS18 for Injectionbiological
Intravenous infusion
ZG005 for Injectionbiological
Intravenous infusion